Liminatus's 1-for-50 split lifted the quote, but not the short's asymmetry

Summary: U.S. short Watchlist, reject for current execution. Liminatus Pharma, Inc. (Nasdaq: LIMN) was marked at $3.645 in the latest finance-feed context at 2026-09-01 21:35:00 UTC, down 6.73575%, after a $3.42 to $3.99 range and 53,453 shares. StockAnalysis records a conflicting $3.72 regular-session close, with 52,386 shares, and no meaningful after-hours change. The company completed a 1-for-50 reverse split effective August 20, after a Nasdaq Hearings Panel granted a brief extension through September 3, 2026 to demonstrate a $1.00 closing bid for ten consecutive trading days. The latest 10-Q reports $3.017 million cash, $3.040 million current liabilities, $2.985 million first-half operating cash use, a $2.531 million first-half net loss, and no commercial revenue line in the reviewed statement of operations. It also reports 67.160 million pre-split common shares as of August 14, 158,881 Series A Preferred shares convertible into common stock only after shareholder approval, and multiple warrant blocks. Public borrow is expensive and scarce, while public short-interest feeds show 4.2 million and 10.3 million shares on different pre-split settlement dates. The structural mismatch is real, but the short fails the Desk's 2:1 risk test: a reference-only base decline to $3.00 is overwhelmed by a credible squeeze to $7.50. A reverse split can cure a quoted bid deficiency without repairing cash, claims, or operating value. This is reference-only research, not personalized financial advice.

Run timestamp: 2026-09-02T11:31:36+08:00 (Asia/Singapore). Quote timestamps, filing dates, catalyst times, and publication time are separate.

Opportunity Ranking

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	Liminatus Pharma (LIMN)	Short	The 1-for-50 split converts a large pre-split denominator into a small implied post-split common base, while a September 3 Nasdaq cure test, preferred conversion claim, and current cash deficit remain unresolved	Aug. 14 10-Q, Aug. 18 8-K, Sep. 1 price and borrow context	Sep. 3 bid-price cure deadline, exchange confirmation, and first post-deadline sessions	Public borrow around 37.7% with 10K shares available; FINRA short-interest snapshots range from 4.2M to 10.3M pre-split shares	Watchlist; reject for current trade	Recent regular-session volume is only 52,386 shares and current spread, depth, locate, and exit liquidity are unverified	The split cures the bid rule, the panel preserves listing, or a squeeze reaches recent post-split highs
2	Stardust Power (SDST)	Short	A development-stage lithium refinery has only about $0.5M cash against first-half operating cash use of $4.0M, but an air permit, DOE research selection, and future financing can keep the project narrative alive	Aug. 13 Q2 release and 10-Q, Sep. 1 market and borrow context	Next financing, construction, project funding, or regulatory milestone; no hard near-term date verified	Public borrow 12.53%, 100K available, 330K short at July 31, 1.0 day to cover	Watchlist; reject	139,860 shares on Sep. 1, but current bid, ask, depth, and exit evidence are missing	Permit and strategic funding can extend the development story while shorting a low-price stock remains costly
3	Cenntro (CENN)	Short	A small cash runway and an active shelf sit beside a $4.09 quote, but the latest session printed only 4,491 shares and no dated event closes the gap	Aug. 14 10-Q, Sep. 1 market and borrow context	No verified near-term closing catalyst	Public borrow about 2.0%, 45K available, 56.4K short, 11.5 days to cover	Reject	Extremely thin regular-session tape; current spread, depth, and exit liquidity are not verified	No catalyst, low short crowding, and a potentially stable post-split quote make the short a carry trade

The screen used the following mechanism-specific searches: reverse split closing bid cure deadline preferred conversion current denominator borrow scarcity, lithium refinery permit cash burn financing runway short interest, and microcap shelf cash runway low volume dated catalyst. Generic earnings-only searches were not used. Repository duplication checks found no dedicated LIMN, SDST, or CENN article or signal in the current week or full Desk thesis archive. LIMN is selected because the September 3 exchange test is the nearest hard catalyst and the 10-Q supplies a concrete denominator, cash, liability, preferred-claim, and warrant bridge.

Selected opportunity: Liminatus Pharma, Inc. (LIMN) common stock, Nasdaq Capital Market.

Why this one now: LIMN has the highest catalyst urgency and the clearest quote-unit versus claim-state disagreement. Its August 18 8-K documents a panel-granted September 3 deadline after a 1-for-50 split. Its August 14 10-Q gives a pre-split common count of 67.160 million, a $3.017 million cash balance, $3.040 million current liabilities, a $2.985 million first-half operating cash drain, and a Series A Preferred claim that is conditional on shareholder approval. The current market-data feeds then disagree sharply about the equity scale. That combination merits a fresh audit, but it does not clear a short trade.

What should surprise the reader: The most important short-side fact is not that Liminatus is pre-clinical. It is that a post-split quote above $1 can be mistaken for a cured capital structure. Nasdaq's test concerns a closing bid and a consecutive-day record. The split changes the unit count and adjusts the instruments. It does not create operating revenue, pay current liabilities, cancel preferred claims, or guarantee a borrowable exit.

Why This Is the Best Opportunity Right Now

The listing chronology is unusually precise. Liminatus disclosed that Nasdaq first cited minimum bid, market-value, and publicly held-share deficiencies. The company appealed a May delisting determination, received a panel decision transferring it to the Nasdaq Capital Market effective August 4, and was given conditions for continued listing. The August 18 8-K says the panel granted a brief extension through September 3, 2026 for the company to demonstrate compliance with Rule 5550(a)(2) by achieving a $1.00 closing bid for at least ten consecutive trading days. The same filing records the board-approved 1-for-50 reverse split, effective at 4:01 p.m. Eastern Time on August 20, with split-adjusted trading expected from August 21. Liminatus August 18, 2026 Form 8-K

The latest quote suggests the split may be approaching its intended bid-price purpose. The post-split reference is above $1 by a wide margin. If every closing bid from August 21 through September 3 meets the rule, the company may obtain written confirmation. If one of the required days fails, the cure state is different. The last trade at $3.645 or the regular-session history at $3.72 cannot independently settle the exchange record. The panel outcome, cure confirmation, suspension state, and any later appeal remain separate states.

The cash bridge does not look repaired. Liminatus's August 14 10-Q reports $3.017 million of cash, $3.040 million of current liabilities, and $3.103 million of total liabilities at June 30. Stockholders' equity was only $300,612. The filing reports a $2.531 million six-month net loss and $2.985 million of six-month operating cash use, partially offset by $5.665 million of financing cash. Management concludes that substantial doubt exists about the company's ability to continue as a going concern and says future operations depend on additional financing. Liminatus June 30, 2026 Form 10-Q

The operating statement is equally important for what it does not show. The reviewed condensed statement of operations lists general and administrative expense of $1.480 million and research and development expense of $1.000 million for the first half, with a $2.480 million operating loss. It does not present a commercial revenue line. The filing describes Liminatus as a pre-clinical biopharmaceutical company developing IBA101, an anti-CD47 antibody. That is future pipeline evidence, not current revenue or cash conversion.

The capital stack is where the simple short story becomes dangerous. As of August 14, Liminatus reported 67,160,362 common shares outstanding before the August 20 split. A mechanical 1-for-50 translation implies roughly 1.343 million post-split common shares, before any later issuance and rounding. The company also reported 158,881.1271 Series A Preferred shares issued in the InnocsAI merger. Each preferred share is described as convertible into 10,000 common shares, subject to adjustment and shareholder approval under Nasdaq rules. A simple split translation would imply approximately 31.8 million post-split-equivalent common shares, but that is stress arithmetic, not current float or a settled claim. The same 10-Q reports pre-split common-stock warrants, placement-agent warrants, inducement warrants, public warrants, and private-placement warrants. Their post-split quantities and exercise prices require contract-level reconciliation.

The market data expose the hidden denominator problem. The finance feed reports a $176.4 million market cap at $3.645. That figure implies about 48.4 million shares at the reported price, which is inconsistent with a simple post-split translation of the August 14 common count. MarketBeat's September 1 history instead shows a market cap near $4.88 million, close to $3.645 multiplied by roughly 1.34 million shares. The vendors do not share one auditable post-action denominator. The correct conclusion is not that one vendor's number proves manipulation. It is that EV, short-interest percentages, and per-share recovery cannot be computed from the unaligned fields.

No candidate clears the Desk's trade-qualified standard once the adverse path and execution gates are included. LIMN wins the research screen because its event is close and its data conflict is decision-relevant. It does not win permission to trade.

Why This Can Move More Than 5% Soon

The September 3 deadline is a hard observation window, but it is not a one-directional catalyst. Four paths can produce a material move:

Cure confirmation: Nasdaq confirms the required closing-bid record, reducing immediate listing pressure and potentially attracting momentum demand.
Unresolved or adverse exchange state: the company fails to demonstrate compliance, receives a further determination, or must pursue another hearing or appeal step.
Claim-state disclosure: the company files shareholder approval, conversion, warrant exercise, registration, settlement, or resale information that changes the post-split denominator.
Squeeze or financing: scarce borrow, a strategic financing, a pipeline update, or a halt and reopening forces demand into a thin tape.

The prior tape demonstrates the range. StockAnalysis records a $9.20 intraday high on August 13 and a $3.42 low on September 1. The same history records only 52,386 shares on September 1, against 11,146,917 shares on August 13. A move of more than 5% is therefore plausible, but its direction and realizability depend on venue, borrow, claim settlement, and order-book depth.

10/5 Asymmetry Gate

The holding window is September 2 through September 9, 2026, covering the final exchange deadline, any written response, and the first regular sessions afterward. The $3.645 finance-feed mark is a reference observation. It is not a verified executable entry.

Test	Calculation or evidence	Result
Reference price	$3.645 at 2026-09-01 21:35:00 UTC; finance-feed context with conflicting regular-history close	Reference only
Favorable base move	Short from $3.645 to $3.000: ($3.645 - $3.000) / $3.645	+17.70% before costs
Credible adverse move	Short from $3.645 to $7.500: ($7.500 - $3.645) / $3.645	-105.76% before costs
Gross favorable-to-adverse ratio	17.70% / 105.76%	0.17:1, far below 2:1
Illustrative borrow carry	37.72% annualized public fee x 7 / 365, only if unchanged	About 0.72% of notional before spread, slippage, recall, buy-in, and path effects
Price-only weighted target	30% x $2.250 + 55% x $3.000 + 15% x $7.500	$3.450
Price-only gross expected short return	1 - $3.450 / $3.645	+5.35% before costs
After-cost value	Entry, broker locate, fee path, current denominator, exchange outcome, spread, depth, and exit liquidity are incomplete	Cannot compute responsibly
Measurement basis	Verified entry or reference-only	Reference-only
Classification	10/5 downside, economics, and execution gates	Watchlist research; reject for current trade

The price-only expected return is not an EV. It is sensitive to a single bottom-case assumption and ignores the possibility of a gap, halt, recall, buy-in, or stale share basis. The modeled adverse rise is more than 100%, so the gross reward-to-adverse-risk ratio fails before costs. A 37.72% public borrow rate is a context observation from an Interactive Brokers feed, not a locked account-level rate. The Desk therefore keeps the signal non-executable.

What Should Surprise the Reader

The reverse split did not reduce the company's authorized common shares. The August 18 filing says the split has no effect on the par value or authorized common and preferred shares. It changes the display unit and adjusts the instruments. A lower post-split denominator can make a market-cap provider look absurdly large if it still uses a pre-split or partially adjusted share count, while a stale short-interest feed can make the short look either crowded or negligible.

The preferred claim is more important than the headline warrant count. Liminatus issued 158,881.1271 Series A Preferred shares in the InnocsAI merger, and the 10-Q says each is convertible into 10,000 common shares subject to shareholder approval. That claim is not current float. It is also not irrelevant. It is a conditional route to a common denominator many times larger than the simple post-split common count. The correct bridge is approval, conversion, settlement, and resale in that order.

The going-concern language is not a timing guarantee. Management says additional equity, debt, or other arrangements may be needed, and that there is no assurance adequate capital will be available. The company raised financing cash in the first half, but financing proceeds are not operating conversion. The next cash and claim filing, not the reverse split itself, decides whether the common has been repaired.

The Setup

Liminatus is a pre-clinical biotechnology company developing an immune-modulating therapy. The current thesis is not that IBA101 cannot work. It is that a post-split quote can look healthy while the balance sheet remains financing-dependent and the common denominator is unsettled.

The state ladder is:

Listing deficiency: Nasdaq notices and a panel exception are documented states.
Reverse split: the 1-for-50 share combination became effective August 20, 2026.
Bid-price cure: the company must demonstrate the required $1.00 closing bid for ten consecutive trading days by September 3; exchange confirmation is not yet verified in this research run.
Common denominator: 67.160 million shares were reported pre-split on August 14; approximately 1.343 million is a mechanical post-split translation, not a current filed count.
Preferred claim: 158,881.1271 Series A Preferred shares are outstanding and their conversion requires shareholder approval; conversion, settlement, and resale are not current common supply.
Warrants: multiple warrant blocks exist with pre-split quantities and terms; post-split adjustment and current exercise or resale are separate states.
Cash conversion: June 30 cash and first-half financing cash are filed; future runway depends on financing and the operating plan.

The market's likely shortcut is to read $3.645 as proof that the split worked and to read the finance-feed $176.4 million market cap as current equity scale. Both shortcuts are unsafe. The split may help satisfy a listing rule. The provider market cap may be stale. Neither establishes durable value for the common.

The Market Price

Observation	Value	Timestamp / session	Source and limitation
Finance-feed context	$3.645, down $0.260 or 6.73575%; open $3.80; high $3.99; low $3.42	Sep. 1, 2026 at 21:35:00 UTC; late context after the regular session	LIMN finance-feed quote; provider session label, bid, ask, spread, depth, and venue are not independently verified
Finance-feed volume and market cap	53,453 shares; $176,411,855 market cap context	Same observation	LIMN finance-feed quote; market cap does not reconcile with the split-adjusted share arithmetic
Regular-session history	$3.72 close, open $3.67, high $3.72, low $3.42, down 3.63%, volume 52,386	Sep. 1, 2026 at 4:00 p.m. Eastern Time	LIMN price history; daily history, not a live top-of-book audit
Recent high-volume context	$7.50 close, high $9.20, volume 11,146,917	Aug. 13, 2026 regular session	LIMN price history; supports gap and squeeze risk, not a fair-value target
Pre-split common denominator	67,160,362 shares	Aug. 14, 2026 filing cover page	Liminatus June 30, 2026 Form 10-Q; a pre-split observation
Mechanical post-split translation	Approximately 1.343 million shares	Calculation from Aug. 14 count and 1-for-50 split	Calculated context only; later issuance, rounding, and current filed denominator are unverified
Post-split after-hours context	$3.645, unchanged in the StockAnalysis page	Sep. 1, 2026 after-hours context	LIMN price history; context only, not an entry
Top of book and exit	Bid, ask, spread, depth, venue quality, volume quality, and realistic exit liquidity	Current run	I do not have sufficient reliable data to quantify this accurately.

I use $3.645 as the reference because it is the latest finance-feed observation and the price level is close to the reported regular-session history. The $3.72 close is retained as a separate daily observation. Neither is an executable entry.

The Mispricing

The market is being asked to price four different states at once:

A reverse split that raises the quoted unit.
A panel deadline that may be cured by a closing-bid sequence.
A pre-clinical company with financing-dependent cash and no commercial revenue line in the reviewed statement.
A common denominator that may be about 1.343 million after the split, alongside a conditional preferred claim that could translate into roughly 31.8 million post-split-equivalent common shares if approved and converted.

The inference is that the quoted price and vendor market-cap field can overstate how much common-equity repair has occurred. The price has already fallen from the August 13 spike, and the market may understand the split mechanics. The contrarian view is not that the market is blind to dilution. It is that the post-split price is being treated as the main fact while the exchange record, current denominator, preferred approval, warrant state, cash runway, and borrow availability remain unresolved.

The market may be right. The 1-for-50 split may complete the bid-price cure. The panel may preserve listing. The preferred conversion may never receive approval. The company has raised cash and can pursue a new financing. A low-volume stock can rise on a small amount of demand. The short thesis must therefore remain a conditional research question, not a claim that LIMN is worthless or that delisting is inevitable.

The Positioning

Public positioning data are useful but not aligned.

Evidence	Observation	Interpretation
Interactive Brokers public borrow feed	37.72% annualized fee and 10,000 shares available as of Aug. 31 at 8:05:51 p.m. Eastern Time	Expensive and scarce public borrow; not an account-level locate or a guarantee through the deadline
CurvedTrading snapshot	About 36.5% borrow and 200 shares available in its Aug. 30 close context; page also shows a later 37.7% and 10K feed	Confirms scarcity directionally, but the time and availability snapshots move quickly
FINRA settlement view A	4.2 million shares short, 6.30% of shares, 1.0 day to cover at the July 31 snapshot	Older pre-split crowding view; the source uses a 67.2 million share denominator
FINRA settlement view B	10.3 million shares short, about 15.4% of shares, 1.0 day to cover at the Aug. 14 snapshot	Newer pre-split view; mechanically equivalent to roughly 206K post-split shares if no later changes occurred
Direct broker state	Locate, utilization, recall, buy-in, settlement, and current availability	Unknown
Holder and flow state	Preferred approval, holder conversion, resale, insider flow, fund flow, option open interest, and dealer exposure	Unknown

Positioning score: 3/5. The borrow evidence is strong enough to make carry and recall material. The short-interest observations are dated and use different settlements and share bases. The public feeds do not prove current crowding after the split. A high borrow rate can destroy a correct directional view if the stock moves sideways while the exchange process resolves.

The Catalyst

Catalyst state	Timing	Observable test	What would accelerate or cancel the path
Reverse split effectiveness	Completed Aug. 20, 2026	Verify the corporate-action record and the broker-adjusted quote and claims	The unit change is not cash repair; an unprocessed CUSIP or claim state can disrupt trading
Nasdaq bid-price cure	By Sep. 3, 2026	Verify the closing-bid record for ten consecutive trading days and written Nasdaq confirmation	Cure reduces the listing pressure; a failed record creates an exchange process, not an automatic zero
Panel, suspension, or appeal state	After any adverse exchange response	Verify the determination, hearing request, stay, suspension, and continued-trading terms	An appeal can preserve trading without repairing the common claim or cash balance
Preferred conversion state	Next shareholder, conversion, or capital-structure filing	Verify shareholder approval, conversion notice, adjusted ratio, settlement, resale, and current denominator	Approval and conversion can add common claims; rejection or holder retention cancels the near-term supply path
Warrant and financing state	Next exercise, inducement, registration, financing, or resale filing	Reconcile adjusted quantity, exercise price, registration, settlement, cash receipt, and holder resale	Cash financing can extend runway and squeeze the short; actual resale or failed financing can pressure the common
Operating and cash bridge	Next quarterly or material operating filing	Separate pipeline, trial spending, cash, liabilities, financing cash, operating cash, and current shares	Clinical progress and fresh cash weaken the short; continued burn without funding supports it

The cheapest falsification sequence is written Nasdaq cure confirmation, followed by the panel or appeal record, then a first regular-session quote and top-of-book audit. Only after that should the current post-split denominator, preferred conversion, warrant settlement, cash receipt, and next operating filing be used to update the thesis.

The Payoff

The payoff map is price-only and reference-based because the entry, current denominator, exchange outcome, broker locate, borrow terms, top-of-book, and exit liquidity are not verified.

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case	30%	$2.250	+38.27% short return before costs	By Sep. 9, 2026	Cure or appeal does not create durable demand, the claim ledger remains unresolved, and the post-split quote retests the lower recent range	Medium
Base Case	55%	$3.000	+17.70% short return before costs	By Sep. 9, 2026	The split holds the quote above $1, but the market waits for current cash, preferred approval, warrant state, and operating proof	Medium
Bottom Case	15%	$7.500	-105.76% short return before costs	During the deadline and first post-deadline sessions	Cure confirmation, panel relief, financing, clinical news, recall, buy-in, halt reopening, or momentum demand creates a squeeze toward the recent post-split range	Low to Medium
Invalidation	n/a	Nasdaq confirms the ten-day cure and a current filing shows stable liquidity, no near-term preferred conversion, holder retention, and improving operating evidence	Remove the thesis and do not wait for a price stop	As observed	The market has a stronger exchange and operating state than the short requires	High when filed

Probability-weighted expected value: Price-only weighted target = (0.30 x $2.250) + (0.55 x $3.000) + (0.15 x $7.500) = $3.450. Against the $3.645 reference, that is an illustrative gross expected short return of 5.35% before borrow, spread, slippage, fees, recall, buy-in, and path effects. If the public 37.72% borrow fee remained unchanged for seven calendar days, simple carry would be about 0.72% of notional. After-cost EV still cannot be computed responsibly because the entry is null, the borrow is not locked, the current denominator is unverified, and a gap or halt can dominate the distribution.

Current market level and timestamp: $3.645 finance-feed context at 2026-09-01 21:35:00 UTC; conflicting $3.72 regular-session close at Sep. 1 4:00 p.m. Eastern Time.

Primary instrument: LIMN common stock only, if all future gates are independently verified.

10/5 favorable base move: 17.70% decline from the reference-only mark.

10/5 credible adverse move: 105.76% underlying rise to the bottom-case level.

10/5 measurement basis: Reference-only, not a verified entry.

10/5 status: Watchlist research; Reject for current trade.

Confidence: High on the August 18 8-K, August 20 reverse-split event, June 30 cash and liability figures, August 14 pre-split common count, and preferred-conversion condition. Medium on the post-split quote and historical prices. Low to Medium on the current denominator, exchange confirmation, preferred approval, warrant adjustment, holder resale, broker locate, recall, spread, depth, and exit liquidity.

The Kill Shot

The strongest mature counterparty argument is that the short is looking at the wrong endpoint. Liminatus does not need to generate commercial revenue this week to satisfy the Nasdaq bid-price rule. The 1-for-50 split raised the quoted unit from a sub-dollar level, the price remained above $1 through the reviewed September 1 session, and the panel granted an extension rather than ordering an immediate delisting. The company has $3.017 million cash, a $15 million PIPE component in its history, fresh financing activity, a clinical asset, and the ability to seek shareholder approval for preferred conversion. A preferred claim is conditional and may never become common stock. The 10.3 million short-interest figure is pre-split and may be misread after a 50-for-1 adjustment. The market may therefore be correctly pricing a listed, financed, option-like biotechnology vehicle rather than a near-term collapse.

That argument is serious and explains the bottom case. The fragile assumption for the short is not that Liminatus has no scientific value. It is that a current quote above $1 will not be mistaken for cash or denominator repair, and that the exchange and broker mechanics permit an orderly exit. A cure confirmation, positive clinical financing, preferred retention, or scarce-borrow squeeze breaks the simple price-to-zero story. The 10/5 ratio is too poor to accept that risk.

What Could Go Wrong

Nasdaq confirms a valid ten-day closing-bid cure, and listing risk disappears faster than the cash and claim concerns can matter.
The panel grants relief or an appeal stays suspension, preserving the venue and giving the market more time to fund the company.
A strategic investor, new PIPE, warrant exercise, or non-dilutive transaction supplies cash and creates a momentum squeeze.
Shareholders do not approve the Series A Preferred conversion, so the largest potential claim never becomes common stock.
The current denominator is larger or the finance-feed market cap is corrected, invalidating the small-float stress arithmetic.
The 4.2 million versus 10.3 million short-interest conflict is mostly a settlement and split-basis artifact, not current crowding.
The price returns to the August 13 high-volume range; a thin borrow pool and a recall or buy-in force a covering price above the bottom case.
The common or warrants halt, reopen with a wide spread, or move to a venue where the short cannot buy back reliably.
The pre-clinical asset produces a positive milestone or the company raises capital before the market demands a current revenue bridge.
The public 37.72% borrow rate rises, availability disappears, or the lender changes terms while the position is open.

What Would Prove This Wrong

The thesis is invalidated by a current sequence showing Nasdaq's written cure confirmation, a stable post-split quote with verified liquidity, no near-term preferred conversion or warrant resale, adequate current cash after liabilities and operating needs, and evidence that the clinical program is funded without a common-equity overhang. A reverse split alone is not invalidation. A provider market-cap correction alone is not invalidation. The exchange, claim, cash, and operating records must agree.

Execution is independently cancelled if a broker cannot provide a current locate, fee, utilization, recall, buy-in, settlement, and availability audit, or if the regular-session quote, bid, ask, spread, depth, venue quality, volume quality, and realistic exit liquidity are not acceptable. The price-only map remains research context even if the listing outcome turns negative.

Risk Audit

Risk	Current evidence	Control
Reverse-split quote illusion	A 1-for-50 split is effective, and the price is above $1, but the split does not create cash or cancel claims	Reconcile pre- and post-split shares, CUSIP, instruments, exchange confirmation, and current cash before treating the quote as repair
Listing cure semantics	The panel set a September 3 deadline for ten closing-bid days	Verify the closing-bid record and written Nasdaq response; do not infer cure or failure from last trade
Preferred conversion	158,881.1271 Series A Preferred shares are convertible into common only after shareholder approval	Track approval, conversion notice, settlement, resale, and current denominator separately; do not call potential shares current float
Warrant adjustment	The 10-Q lists 9.6255M common-stock warrants, 20.688M inducement warrants, placement warrants, and public warrants on a pre-split basis	Recalculate contract-adjusted quantities and prices; require exercise, registration, settlement, cash receipt, and resale evidence
Cash quality	June 30 cash was $3.017M against $3.040M current liabilities, with $2.985M first-half operating cash use and substantial-doubt language	Require the next cash, liability, financing, and operating-cash bridge; financing cash is not operating conversion
Borrow and recall	Public borrow is about 37.7% with only 10K shares in a dated feed, and another snapshot showed 200 shares	No entry without account-level locate, fee, utilization, recall, buy-in, settlement, and availability through the catalyst
Short-interest conflict	Dated public sources report 4.2M or 10.3M pre-split shares short	Preserve both dates and share bases; cap positioning confidence at 3/5 and do not extrapolate current crowding
Market-cap conflict	Finance feed reports $176.4M while post-split arithmetic and other vendor context imply roughly $5M	Do not compute EV, recovery, or per-share value from unaligned timestamps; use price-only scenarios
Gap and halt	The stock traded 11.1M shares on Aug. 13 and only 52,386 on Sep. 1, with a recent $9.20 high	No market order, leverage, margin, options, price-floor logic, session-low short, or short through a halt
Clinical and financing counterparty	The company is pre-clinical and financing-dependent, but a clinical update or new capital can create demand	Treat pipeline and financing as future evidence; re-underwrite after each filing or material milestone

Best Trade Strategy

This is a Watchlist research expression, not an executable short.

Instrument: LIMN common stock only. No options, leverage, margin, market order, or no-locate short is supported by the current evidence.
Price basis: The reference is $3.645 at the Sep. 1 finance-feed observation. The $3.72 StockAnalysis regular close is a separate context mark. Neither is an executable entry.
Entry state: entry.price = null; execution.can_execute = false.
Required exchange gates: verified closing-bid count, Nasdaq cure confirmation or current determination, panel state, suspension state, appeal request, and any stay.
Required market gates: fresh regular-session quote; bid, ask, spread, depth, venue quality, volume quality, and realistic exit liquidity.
Required short gates: broker-level locate, borrow rate and availability, utilization, recall, buy-in, settlement, and carry through the deadline and any appeal.
Required capital gates: current post-split common denominator, preferred approval and conversion state, warrant adjustment and settlement, registration, resale, current cash, current liabilities, and operating cash.
Conditional targets: $2.250 top, $3.000 base, and $7.500 bottom are scenario levels only. They are not guaranteed exits or trade instructions.
Horizon: Sep. 2 through Sep. 9, 2026. Re-underwrite after the September 3 exchange response, first post-deadline regular sessions, any halt or reopening, each claim filing, and the next cash-flow update.
Alternative expression: A defined-loss option could limit nominal loss, but no live LIMN option chain, spread, open interest, assignment terms, or maximum-loss analysis was verified. No option expression is recommended by this screen.
Do not trade: Do not short the post-split quote merely because the pre-split business was distressed. Do not treat the reverse split, the finance-feed market cap, the preferred claim, warrant capacity, public borrow availability, or a dated short-interest figure as a price floor or current float.

Sources

Liminatus August 18, 2026 Form 8-K - Nasdaq deficiency history, panel transfer, September 3 extension, 1-for-50 split, effective time, and authorized-share treatment.
Liminatus June 30, 2026 Form 10-Q - cash, current liabilities, equity, net loss, operating cash use, going-concern language, pre-split common count, preferred shares, and warrant ledger.
Nasdaq Listing Rules - $1.00 minimum bid and ten-consecutive-business-day cure framework.
LIMN finance-feed quote - latest price, range, volume, change, and provider market-cap context at 2026-09-01 21:35:00 UTC.
LIMN regular-session and after-hours price history - September 1 price conflict, volume, recent high-volume event, and prior range; daily history is not a top-of-book audit.
LIMN market-cap and price history context - September 1 market-cap context using a split-adjusted share scale; vendor fields conflict with the finance feed.
LIMN public borrow and short-interest context - public borrow, availability, dated FINRA short interest, days to cover, dilution, and cash-runway context; not an account-level locate.
LIMN Short Interest Tracker - alternative dated borrow, availability, and July 31 FINRA short-interest context.
LIMN Interactive Brokers borrow history - dated public borrow fee and availability feed.
Stardust Power August 13, 2026 Q2 results - ranked SDST alternative cash, operating cash, financing, permit, and project context.
SDST regular-session and after-hours price history - ranked alternative September 1 price, volume, and recent project-event tape.
SDST Short Interest Tracker - ranked alternative public borrow, availability, and dated short-interest context.
Cenntro June 30, 2026 Form 10-Q - ranked CENN alternative current filing and cash-runway source.
CENN regular-session and after-hours price history - ranked alternative September 1 price and 4,491-share volume.
CENN public borrow and short-interest context - ranked alternative borrow, availability, short-interest, and days-to-cover data.

Research Quality Scorecard

Criterion	Score	Reason
Market disagreement	5/5	A split-adjusted quote, exchange cure clock, current cash deficit, preferred claim, and conflicting market-cap denominator create a specific price-positioning-catalyst tension
Evidence base	4/5	The August 18 8-K and August 14 10-Q are paired with current price history and multiple public borrow feeds
Positioning and flows	3/5	Borrow scarcity is clear, but short-interest settlement dates and share bases conflict; holder flow and order-book evidence are missing
Catalyst path	4/5	The September 3 cure test, exchange response, appeal state, claim filings, and next cash bridge are observable
Payoff architecture	2/5	The base decline clears 10%, but the credible adverse rise is above 100% and the gross ratio is 0.17:1
Invalidation discipline	4/5	Exchange confirmation, preferred approval, warrant settlement, cash, denominator, and price-acceptance tests are explicit
Differentiated insight	5/5	Separates quote-unit repair from cash repair, preferred claims, warrant states, vendor market-cap mismatch, and borrow scarcity
Client value	4/5	The state ladder is useful even though it rejects an executable short

Total: 31/40. Classification: Watchlist research; Reject for current execution. The score cannot override the failed 10/5 adverse bound, null entry, unverified current denominator, punitive borrow, or missing exit evidence.

Bottom Line

LIMN is the strongest fresh U.S. short research candidate because its September 3 Nasdaq cure test is close and the 1-for-50 split creates a clean example of quote repair without operating or capital-structure repair. The company reports limited cash, substantial-doubt language, no commercial revenue line in the reviewed statement, and a conditional preferred claim that could be much larger than the simple post-split common denominator. But the same setup carries the short's main danger: a panel extension, cure confirmation, financing, preferred retention, recall, or thin-float squeeze can overwhelm a correct long-term concern. The reference-only weighted map is not an executable edge, and the 0.17:1 gross reward-to-adverse-risk ratio rejects the trade. Keep entry.price null and execution.can_execute false until the exchange, broker, market-structure, claim, cash, and denominator evidence agree.

AI Illustration Prompt

Create a realistic editorial illustration for The Mispricing Desk about Liminatus Pharma (LIMN) after a 1-for-50 reverse split and immediately before the September 3, 2026 Nasdaq bid-price cure deadline: a sober securities operations room with a large mechanical counter changing from 67.160M PRE-SPLIT COMMON to ~1.343M POST-SPLIT IMPLIED, while a separate exchange panel reads $1.00 CLOSING BID / 10 CONSECUTIVE TRADING DAYS / CURE CONFIRMATION PENDING. Place a calendar marked SEP 3 beside two conditional paths, one blue-gray labeled NASDAQ CURE CONFIRMATION and one muted red labeled PANEL / APPEAL / SUSPENSION STATE, with no path shown as inevitable. In the foreground, show a cash ledger reading $3.017M CASH, $3.040M CURRENT LIABILITIES, -$2.985M H1 OPERATING CASH, $300.6K STOCKHOLDERS' EQUITY, and a restrained document note PRE-CLINICAL / NO COMMERCIAL REVENUE LINE IN REVIEWED STATEMENT. Next to it, show a transparent Series A Preferred certificate labeled 158,881.1271 SHARES / 10,000 COMMON PER SHARE / SHAREHOLDER APPROVAL REQUIRED, with a projected but visibly conditional annotation ~31.8M POST-SPLIT-EQUIVALENT CLAIM, NOT CURRENT FLOAT. Add a separate warrant ledger with adjusted quantities marked UNRECONCILED. On a market monitor, show two conflicting scales: $3.645 FINANCE FEED / $176.4M PROVIDER MARKET CAP and ~$4.9M SPLIT-SCALE EQUITY CONTEXT, connected by a red line labeled DENOMINATOR MISMATCH. Add a glass borrow panel reading 37.72% PUBLIC BORROW / 10K AVAILABLE, plus two dated short-interest cards 4.2M JUL 31 and 10.3M AUG 14 PRE-SPLIT, with a red stamp BROKER LOCATE UNVERIFIED. Include a small clinical research folder and a quiet microscope silhouette in the background, but keep the financial state dominant. Make the distinction between quoted-unit repair, listing cure, cash, preferred claims, warrants, short-interest basis, and executable exit risk visually unmistakable. Use charcoal, warm paper, muted regulatory blue, brushed aluminum, clinical teal, amber, and one controlled red accent; documentary financial-journalism lighting; tactile paper, glass, steel, and matte display textures; no rockets, coins, generic candlestick charts, hype imagery, invented logos, or personalized advice. Add a subtle readable The Mispricing Desk watermark on the room wall. Wide 16:9 composition, premium magazine art direction, precise typography, sober, tense, and unresolved.